Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

This study has been withdrawn prior to enrollment.
Boehringer Ingelheim
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: April 17, 2013
Last updated: December 18, 2013
Last verified: December 2013
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: April 2015
  Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)